Vendor Intelligence Report: TP Peptide

Published 2 Jul 2026. 14-page investigative report on who is behind TP Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, TP Peptide records 4 passes, 0 failures, and a 100% overall pass rate. That headline is clean, but narrow: the entire Finnrick record covers Tirzepatide only. For buyers seeking Tirzepatide through the examined Telegram/LookChem channel, the signal is directionally favorable; for every other peptide, the report has no lab basis for extrapolation. The full report also shows how the rating should be read against stricter methodology views.

The off-ledger issue is accountability. TP Peptide is presented less like a conventional web storefront and more like a Telegram sales channel tied to a LookChem marketplace profile under the Tuobao Trading subdomain. The LookChem Credibility page shows core verification documents as No approved, while Shenzhen/Hong Kong, OpenCorporates and Delaware searches did not surface a matching legal entity under the investigated names. That does not disprove private paperwork; it does mean public recourse is thin.

The contact layer is similarly light: Mr. Linmo, Ms. Anna, Hong Kong phone numbers, a Shenzhen address, and a personal Gmail account, with no LinkedIn personnel match tied to TP Peptide. Researchers also found no meaningful public affiliate/coupon network, no documented copycat domain, and no visible complaint cluster, but the reputation surface is quiet rather than mature. The practical read is specific: TP Peptide is most defensible as a Tirzepatide-only, verify-your-lot option, not a broadly documented peptide supplier.

Inside the full report:

  • Per-product Finnrick laboratory record and methodology-divergence chart for the single tested product
  • LookChem About and Credibility page captures showing contact details and document-verification status
  • Registry checks across Shenzhen/Hong Kong, OpenCorporates and Delaware
  • Contact-infrastructure review covering Hong Kong numbers, Shenzhen address, Gmail and personnel-search dead ends
  • Affiliate and reputation scan across X, coupon sites, Reddit/forum surfaces and documented caveats
  • Risk matrix and buyer guidance separating Tirzepatide use from untested peptide sourcing

Risk assessment

  • Corporate-accountability risk — high: No matching corporate registration was verified for TP Peptide / Tuobao Trading, and LookChem shows No approved for core corporate documents; Telegram/Gmail sales leave limited recourse.
  • Sourcing-traceability risk — medium: Tirzepatide has 4 Finnrick passes, but the actual manufacturer, facility and lot-level QA controls were not identified; no public COA program was documented.